XXB 750
XXB750 is an investigational drug developed by Novartis Pharmaceuticals, designed to treat resistant hypertension (rHTN) and heart failure with reduced ejection fraction (HFrEF). It functions as a natriuretic peptide receptor 1 (NPR1) agonist and is administered via subcutaneous injection.
In a Phase II clinical trial involving patients with rHTN, XXB750 demonstrated safety and tolerability, with peak plasma concentrations occurring between 4 to 10 days post-administration and a half-life ranging from 15 to 25 days at doses of 60 mg or higher. These findings suggest that XXB750 could offer a new therapeutic option for individuals with treatment-resistant hypertension. [1]
Additionally, XXB750 has been evaluated in patients with HFrEF. However, a Phase II proof-of-concept and dose-finding study in this patient population was terminated in November 2024 due to a sponsor decision. [2]
While XXB750 has shown promise in early clinical trials, further research is necessary to fully establish its efficacy and safety profiles for the treatment of resistant hypertension and heart failure with reduced ejection fraction.
- ^ nationalheartinstitute.org https://nationalheartinstitute.org/news/blog/the-xxb-750-resistant-hypertension-clinical-trial-results?utm_. Retrieved 2024-12-13.
{{cite web}}: Missing or empty|title=(help) - ^ "XXB750 / Novartis". delta.larvol.com. Retrieved 2024-12-13.